VHH – pathogen inhibitor adduct leads to dual immune response to treat and prevent infections

Our adduct binds to the immunoglobulin kappa (Igκ) light chain of all naturally circulating immunoglobulins (IgG, IgM, IgA & IgE, etc), and brings together the infected cells and a diverse set of Fc Receptor (FcR+) effector cells. The recruitment of effector cells facilitates rapid and effective activation of both B and T cell functions.

Binding to the immunoglobulin kappa chain of all all IgG, IgM, IgA and IgE


Applications of KappaLink

Cerberus’ KappaLink platform has broad implications to target various types of infections as well as cancer.

Cerberus’ solution to unmet needs in infectious disease

Unmet needs

Despite major improvements in healthcare worldwide, infectious diseases continue to take heavy tolls on global populations. They are a leading cause of death worldwide, particularly in low-income countries, especially in young children. Lower respiratory infections remained the world’s most deadly communicable disease, ranked as the 4th leading cause of death globally (2.4mm death in 2019). As the most recent Covid-19 pandemic ripples through the world, it only further highlights the urgent need of timely and effective therapeutic solutions to the deadliest infectious diseases.

Our Solution

Cerberus’ highly modular adduct engages diverse Ig isotypes and subclasses, resulting comprehensive immune responses and immediate protection in one dose. It is able to maintain efficacy through various administration routes, including nasal spray. Furthermore, KappaLink has the potential of targeting multiple diseases via a single formulation.